Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Oral Dose Safety Study of SEP-363856 in Japanese Subjects with Schizophrenia
jRCT2080225100Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ulotaront in schizophrenia (4 cohorts), sponsored by Sumitomo Pharma. Primary endpoint: Primary safety and tolerability outcomes. Started Feb 2020; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080225100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225100.